The regulatory dimension — is this problematic?8 May 2026 12:54
This is the most important question and the one that needs careful thought.
If a transaction is live, if Heads of Terms are being negotiated, if a CDA is in force with a counterparty, then PG endorsing a document that speculates accurately about the deal structure, the counterparty type, the valuation, and the timeline could potentially constitute selective disclosure of price-sensitive information, even if the underlying document contains only public sources.
The endorsement itself, not the document, is the new piece of information. The market now knows that PG has read a document that says a transaction is imminent and muted values stated, and he has not corrected it. That is information.
▪️ If there is no live transaction, the endorsement is a strategic communications move to build market narrative ahead of a deal announcement, entirely legitimate
▪️ If there is a live transaction, the endorsement is more complicated and PG and Flagstaff will have thought carefully about where the line is
Practically — what does this mean for timing?
An endorsement of a document that concludes "the clock isn't just ticking, it may have already struck", combined with the 90-day rig lead time analysis pointing to a decision being made right now is the strongest possible signal short of an actual RNS that something is imminent.
CEOs of listed companies do not endorse M&A theses about their own company for fun. They endorse them when the thesis is right, when the timing is right, and when they want the market to be prepared for what is coming.